Esophageal Squamous Cell Carcinoma Companies

BeiGene receives US FDA Breakthrough Therapy Designation for tislelizumab (an anti-PD-1 monoclonal antibody) for the treatment of locally advanced unresectable or metastatic ESCC, potentially accelerating its pathway to market.

AstraZeneca's IMblaze 410 trial investigating Imfinzi (durvalumab) in combination with chemotherapy met its primary endpoint, showing improved overall survival in patients with stage III resectable ESCC after surgery.

Seagen secures Fast Track designation from the US FDA for tucatinib (a HER2 tyrosine kinase inhibitor) in combination with other standard therapies for advanced ESCC with HER2 alterations.

Eli Lilly and Innovent Biologics form a strategic partnership to develop and commercialize innovative therapies for ESCC and other cancers. This collaboration combines their expertise and resources to accelerate drug development and market access.

Bristol-Myers Squibb and Checkmate Pharmaceuticals agree to co-develop and commercialize OPB-838, a novel drug candidate with potential for ESCC treatment, leveraging their combined strengths in clinical development and commercialization.

• Hoffmann-La Roche Ltd


• AstraZeneca


• Chia Tai Tianqing Pharmaceutical Group Co. Ltd.


• Seagen Inc.


• Eli Lilly and Company


• Glaxosmithkline Plc


• Novartis AG


• Beijing Shenzhou Cell Biotechnology Group Co., Ltd.


• Jacobio Pharmaceuticals Group Co., Ltd